Trials / Completed
CompletedNCT05723978
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 520 (actual)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Selective extended dissection of pancreaticoduodenectomy | An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2022-07-01
- Completion
- 2022-12-01
- First posted
- 2023-02-13
- Last updated
- 2023-02-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05723978. Inclusion in this directory is not an endorsement.